More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...

Growth in Eliquis drug also led to an upside in the top line. Consequently, the company raised its annual earnings guidance. Following this, the stock also rallied. BMY is banking on newer drugs ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

The impact of the IRA on drug pricing, particularly for Eliquis, has been a focal point for investors. BMY's ability to navigate these regulatory changes while maintaining profitability will be ...

This medication is an anticoagulant ... avoid coadministration with strong dual inhibitors. • Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk ...